ClinicalTrials.gg
CompletedNCT07942441Updated Nov 17, 2026

The Effect of Mindfulness-Based Psychoeducation on Psychological Resilience and Insight in Individuals Diagnosed With Schizophrenia

An interventional study of Mindfulness-Based Psychoeducation in SCHIZOPHRENIA 1 (Disorder), Mindfulness and Insight, sponsored by Dicle University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionSchizophreniaRegistry: Psychological Well-BeingReclassifiedWhy we changed it
Registry
Psychological Well-Being — the first condition term the registry derived for this study.
ClinicalTrials.gg
Schizophrenia
Why
  1. Psychological Well-Being is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Schizophrenia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dicle University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2025, registered Aug 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 96 studies in Schizophrenia with a site in Turkey — 19 open to participants now, 20 under way, none of them phase 3. Schizophrenia · Turkey.

Enrollment
33rd of 81
66 · median 60
Started
2025
with 16 others
No phase
57 of 96
16 open now
Registered
93rd of 96
by date

Among the 96 studies in Schizophrenia with a site in Turkey, this one is the 33rd largest by enrollment of the 81 interventional ones that give a count, is one of 17 that started in 2025, is one of 57 with no phase, and was the 93rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

19 of the 96 studies in Schizophrenia with a site in Turkey are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Schizophrenia with a site in Turkey, or all of them as a file.
02

Study summary

  • Objective:** This study was designed to evaluate the effects of mindfulness-based psychoeducation on psychological resilience and insight among individuals diagnosed with schizophrenia.
  • Methods:** This randomized controlled study with a pretest-posttest control group design was conducted at a Community Mental Health Center between January and December 2025. The study included 66 individuals diagnosed with schizophrenia, with 32 participants allocated to the intervention group and 34 to the control group. Participants in the intervention group received a structured mindfulness-based psychoeducation program consisting of one preparatory session and eight group-based sessions, whereas participants in the control group did not receive this intervention. Both groups continued to receive routine psychiatric care. Data were collected using the Descriptive Characteristics Form, the Brief Resilience Scale (BRS), and the Birchwood Insight Scale (BIS). Psychological resilience and insight were assessed before and after the intervention to evaluate potential changes associated with mindfulness-based psychoeducation.
Read the detailed description

**Detailed Description**

Schizophrenia is a chronic psychiatric disorder associated with disturbances in thought, perception, emotion, and behavior that can substantially affect psychosocial functioning and recovery. Psychological resilience and insight are important components of recovery-oriented care in individuals diagnosed with schizophrenia. Psychological resilience refers to the ability to adapt to stressful experiences and recover from adversity, whereas insight involves awareness of the illness, recognition of psychiatric symptoms, and understanding of the need for treatment. Psychosocial interventions targeting these dimensions may complement routine pharmacological treatment.

Mindfulness-based psychoeducation combines structured educational activities with mindfulness practices that emphasize present-moment awareness, non-judgmental acceptance, and adaptive responses to psychological experiences. This approach aims to strengthen coping strategies, promote awareness of illness-related experiences, and support engagement in psychiatric treatment. The present study was designed to evaluate the effects of mindfulness-based psychoeducation on psychological resilience and insight among individuals diagnosed with schizophrenia.

**Study Design and Setting**

This study employed a randomized controlled pretest-posttest design and was conducted between January and December 2025 at a Community Mental Health Center (CMHC) affiliated with a research and training hospital in Türkiye. The center provides community-based psychiatric treatment, rehabilitation, psychoeducation, individual counseling, group therapy, and psychosocial support to individuals with severe mental disorders.

Participants were individuals diagnosed with schizophrenia who were receiving regular psychiatric follow-up and antipsychotic treatment at the CMHC. Participants were clinically stable and in remission at enrollment. Routine psychiatric treatment and follow-up continued throughout the study, and no medication modifications were introduced as part of the research protocol.

Participants were assigned to intervention and control groups using computer-generated block randomization with a block size of four. Because of the nature of the psychoeducational intervention, blinding of participants and researchers was not feasible. Data obtained from the intervention and control groups were coded before statistical analysis to reduce potential assessment bias.

**Mindfulness-Based Psychoeducation Intervention**

The intervention consisted of a structured mindfulness-based psychoeducation program adapted from mindfulness-based stress reduction (MBSR) principles and relevant psychoeducational approaches.

Before the intervention, a preparatory session was conducted to introduce participants to the program and complete baseline assessments. The intervention subsequently consisted of eight weekly group sessions, each lasting approximately 45-50 minutes.

The intervention was delivered face-to-face by a researcher who had previously completed MBSR training. Participants in the intervention group were organized into four smaller groups of approximately eight or nine individuals. Sessions were conducted in a separate, quiet meeting room at the CMHC to provide an appropriate environment for mindfulness practices and minimize potential contamination between study groups.

The program integrated mindfulness practices and psychoeducational activities intended to promote present-moment awareness, non-judgmental observation of internal experiences, psychological adaptation, and illness awareness. Participants were assigned practice-related homework following each session to encourage the application of the techniques outside the group setting. Make-up sessions were arranged when necessary to support continuity of participation.

The control group did not receive the mindfulness-based psychoeducation intervention. Participants in both groups continued to receive routine psychiatric care and follow-up services provided by the CMHC.

**Outcome Assessment**

Psychological resilience and insight were assessed before and after the intervention using the Brief Resilience Scale (BRS) and the Birchwood Insight Scale (BIS), respectively. Sociodemographic and clinical characteristics were collected using a Descriptive Characteristics Form.

The BRS was used to assess participants' perceived ability to recover from stressful experiences, whereas the BIS was used to evaluate illness awareness, recognition of symptoms, and awareness of the need for treatment.

**Safety Monitoring**

Participants were monitored throughout the study for potential adverse events associated with mindfulness-based psychoeducation. Safety monitoring included physical discomfort, dizziness, falls, deterioration in psychiatric symptoms, hospital admissions, and other potential intervention-related concerns.

Participants' clinical conditions were routinely followed by healthcare professionals at the CMHC, including psychiatrists, psychologists, and nurses. Any adverse events or safety concerns reported by participants were documented and evaluated by the research team.

**Ethical Considerations**

The study received approval from a university ethics committee (Approval No: 2024/717838), and institutional permission was obtained from the CMHC. All participants were informed about the purpose and procedures of the study, confidentiality of their information, and their right to withdraw at any time. Written informed consent was obtained before participation. The study was conducted in accordance with the principles of the Declaration of Helsinki.

03

Conditions studied

  • SCHIZOPHRENIA 1 (Disorder)
  • Mindfulness
  • Insight
  • Resilience
  • Mental Health

Browse trials for

Keywords

  • Insight
  • Mindfulness
  • Psychoeducation
  • Psychological Resilience
  • Psychiatric Nursing
  • Schizophrenia
04

In context

Schizophrenia Reclassified

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

This study's enrollment of 66 is close to the median of 70 across 2,953 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Dicle University is the lead sponsor of 29 studies on the registry; 7 are open to participants now.

Compared within Schizophrenia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychological Well-Being. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: • Being open to communication and collaboration,

  • Being 18 years and above,
  • Being diagnosed with schizophrenia (The individuals participating in the study were diagnosed with schizophrenia by a psychiatrist according to criteria)
  • Regularly attending at CMHC (at least 2 days per a week)
  • Being at least primary school degree

Exclusion Criteria:

    • Being in acute exacerbation period (the period when the positive symptoms of the illness are intense)

      • Having comorbid mental illness identified by CMHC records
      • Having dementia or any other organic mental disorder identified by CMHC records
      • Having intellectual disability identified by CMHC records
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Inclusion Criteria * Being open to communication and collaboration, * Being 18 years and above, * Being diagnosed with schizophrenia (The individuals participating in the study were diagnosed with schizophrenia by a psychiatrist according to DSM-5 criteria) * Regularly attending at CMHC (at least 2 days per a week) * Being at least primary school degree Exclusion Criteria * Being in acute exacerbation period (the period when the positive symptoms of the illness are intense) * Having comorbid mental illness identified by CMHC records * Having dementia or any other organic mental disorder identified by CMHC records * Having intellectual disability identified by CMHC records

    Other: Mindfulness-Based Psychoeducation

  • No intervention
    Control Group

    No intervention

Interventions

  • OtherMindfulness-Based Psychoeducation

    Nursing Intervention An adapted mindfulness-based psychoeducation program informed by MBSR principles. The Mindfulness-based psychoeducation was carried out for the experimental group. The researcher implementing the mindfulness-based psychoeducation completed the MBSR program led by MBSR instructor Prof. Dr. Aysel KARACA (Accreditation No: TTI-01202001) between May 27 and July 15, 2021, and earned a certificate of participation. The training was carried out by the researcher in the meeting room at CMHC. The experimental group was divided into four groups, each containing eight or nine participants. The researcher provided face-to-face and group training once a week for eight weeks (Except for the week when the preparatory session is held). Each session was 45-50 minutes on average. In addition, make-up sessions were held for individuals who could not attend the original sessions (Thanks to the same topic being presented across four different sessions within a single week, the individu

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Brief Resilience Scale (BRS) Total Score

    Psychological resilience was assessed using the Brief Resilience Scale (BRS), a six-item self-report instrument designed to measure the ability to recover from stressful experiences. Each item is rated on a five-point Likert scale ranging from 1 to 5. Items 2, 4, and 6 are reverse-scored. The scores of all six items are summed to obtain a single total score ranging from 6 to 30 points, with higher scores indicating greater psychological resilience. The outcome was evaluated by comparing the BRS total scores obtained during the preparatory session (baseline assessment) and the eighth intervention session (post-test assessment).

    Time frame: Baseline (before intervention) and week 8 (immediately after completion of the intervention)

Secondary outcomes

  1. Change From Baseline in Birchwood Insight Scale (BIS) Total Score

    Illness insight was assessed using the Birchwood Insight Scale (BIS), an eight-item self-report instrument evaluating awareness of illness, recognition of symptoms, and awareness of the need for treatment. Each item is scored from 0 to 2. The scores from items 1, 2, 7, and 8 are summed directly, while the sum of items 3, 4, 5, and 6 is divided by two and added to the total score. These item scores are combined to obtain a single BIS total score ranging from 0 to 12 points, with higher scores indicating greater insight. The outcome was evaluated by comparing the BIS total scores obtained during the preparatory session (baseline assessment) and the eighth intervention session (post-test assessment).

    Time frame: Baseline (before intervention) and week 8 (immediately after completion of the intervention)

08

Study locations

1 site
  • a community mental health center affiliated to a Diyarbakır Gazi Yaşargil research and training hospital
    Diyarbakır, 21280, Turkey (Türkiye)
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Dec 2025, 11 months.

Of 762 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 11 months is below that.

Counting every sponsor, half of 775 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Nov 17, 2026
StartActual
Jan 1, 2025
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07942441
Lead sponsor
Dicle University
Responsible party
Tülay YILDIRIM ÜŞENMEZ (Associate Professor Doctor, Dicle University) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 1, 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion